Exposure–response modeling of peficitinib efficacy in patients with rheumatoid arthritis

Junko Toyoshima | Atsunori Kaibara* | Mai Shibata | Yuichiro Kaneko | Hiroyuki Izutsu | Tetsuya Nishimura

Astellas Pharma Inc., Tokyo, Japan

Correspondence
Junko Toyoshima, Clinical Pharmacology and Exploratory Development, Astellas Pharma Inc., 2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo 103-8411, Japan.
Email: junko.toyoshima@astellas.com

Funding information
Astellas Pharma Inc.

Abstract
The aim was to analyze the relationship between peficitinib exposure and efficacy response according to American College of Rheumatology (ACR) 20 criteria and 28-joint disease activity score based on C-reactive protein (DAS28-CRP) in rheumatoid arthritis (RA) patients, and to identify relevant covariates by developing exposure–response models. The analysis incorporated results from three multicenter, placebo-controlled, double-blind studies. As an exposure parameter, individual post hoc pharmacokinetic (PK) parameters were obtained from a previously constructed population PK model. Longitudinal ACR20 response rate and individual longitudinal DAS28-CRP measurements were modeled by a non-linear mixed effect model. Influential covariates were explored, and their effects on efficacy were quantitatively assessed and compared. The exposure–response models of effect of peficitinib on duration-dependent increase in ACR20 response rate and decrease in DAS28-CRP were adequately described by a continuous time Markov model and an indirect response model, respectively, with a sigmoidal $E_{\text{max}}$ saturable of drug exposure in RA patients. The significant covariates were DAS28-CRP and total bilirubin at baseline for the ACR20 response model, and CRP at baseline and concomitant methotrexate treatment for the DAS28–CRP model. The covariate effects were highly consistent between the two models. Our exposure–response models of peficitinib in RA patients satisfactorily described duration-dependent improvements in ACR20 response rates and DAS28-CRP measurements, and provided consistent covariate effects. Only the ACR20 model incorporated a patient's subjective high expectations just after the start of the treatment. Therefore, due to their similarities and differences, both models may have relevant applications in the development of RA treatment.

Clinical trial registration: NCT01649999 (RAJ1), NCT02308163 (RAJ3), NCT02305849 (RAJ4).

KEYWORDS
modeling and simulation, pharmacometrics, population analysis, rheumatoid arthritis
INTRODUCTION

Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory autoimmune disease that targets the synovial tissues. Disease-modifying antirheumatic drugs (DMARDs) have an important role in inhibiting disease progression; in patients who respond inadequately or are intolerant to conventional synthetic (cs)DMARDs, biological (b) DMARDs and targeted synthetic (ts)DMARDs are recommended as part of combination therapy. However, unmet therapeutic needs in RA remain: for example, 30–40% of patients are unresponsive to bDMARDs. It is therefore crucial to develop alternative treatments for patients with RA and an inadequate response to existing drugs.

Peficitinib is an orally bioavailable inhibitor of the Janus kinase (JAK) family: JAK1, JAK2, JAK3, and tyrosine kinase 2. The JAK/signal transduction and activator of transcription (STAT) signaling pathway is implicated in the pathogenesis of inflammatory and autoimmune diseases, and is thus a therapeutic target to treat RA.

The efficacy and safety of peficitinib, as monotherapy or in combination with csDMARDs, for treatment of patients with RA have been demonstrated previously in phase 2 and phase 3 randomized, double-blind, placebo-controlled studies conducted in Asian countries (Japan, Korea, and Taiwan). Peficitinib has been approved in Japan, Korea, and Taiwan as an RA treatment in patients who have an inadequate response to conventional DMARD therapy. Previously, prior exposure–response models were developed using the result of the phase 2 study and the results from these supported the rationale behind the dosing used in the phase 3 studies (not published).

The objectives of this study were a) to develop exposure–response models using the results from the phase 2 and phase 3 studies for the relationship between peficitinib exposure and two efficacy outcomes: American College of Rheumatology (ACR) 20 criteria and 28-joint disease activity score based on C-reactive protein (DAS28-CRP), which were the primary and one of the secondary endpoints, respectively, in the phase 2 and 3 studies; b) to explore the relevant covariates underlying the differences in clinical response; and c) to clarify the similarities and differences of the two models, in order to reveal the optimal use of peficitinib in patients with RA.

METHODS

2.1 Design of the clinical studies

For this exposure–response analysis of peficitinib treatment for RA, the results from three multicenter, placebo-controlled, double-blind studies were included (the RAJ1 phase 2 study and the RAJ3 and RAJ4 phase 3 studies). Study designs, treatment arms, and time points for assessment of ACR20, DAS28-CRP, and peficitinib plasma concentrations are summarized in Table 1. All clinical studies were conducted in accordance with ethical principles of the Declaration of Helsinki, Good Clinical Practice, and the International Conference for Harmonization guidelines, and were approved by the relevant institutional review boards. All patients provided written informed consent.

2.2 Exposure parameters

A population pharmacokinetic (PK) model for peficitinib in RA patients was previously constructed as a two-compartment model with sequential zero- and first-order absorption and lag time using NONMEM. This model was utilized to obtain individual post hoc
### TABLE 1  Peficitinib clinical studies included in the analysis

| Study number (Clinical Trials.gov identifier) | Indication | Study design | Treatment | No. of patients<sup>a</sup> | Treatment duration (weeks) | ACR20 response | DAS28-CRP | Peficitinib plasma trough concentrations | Peficitinib concentrations post-administration | Ref. |
|-----------------------------------------------|------------|--------------|-----------|-----------------------------|---------------------------|----------------|---------|----------------------------------------|-----------------------------------------------|------|
| RAJ1 (NCT01649999)                           | RA; no concomitant or recent DMARD therapy | Phase 2b, randomized, double-blind, placebo-controlled, parallel-group | Placebo, 25 mg, 50 mg, 100 mg, 150 mg | 281                          | 12                        | Weeks 1, 2, 4, 8, and 12 | Baseline and weeks 1, 2, 4, 8 and 12 | Weeks 1, 2, 4, 8 and 12 | N/A                                          | 9    |
| RAJ3 (NCT02308163)                           | RA; inadequate response to, or intolerance of, prior DMARDs, including MTX | Phase 3, randomized, double-blind, placebo-controlled, active-referenced, parallel-group | Placebo to 100 mg or 150 mg at Week 12, 100 mg, 150 mg, open-label etanercept<sup>b</sup> | 307                          | 52                        | Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 | Baseline and every 4 weeks until 52 weeks | Weeks 4, 8, 12, 20, 28, 40, and 52 | Week 4 or 8 | 10 |
| RAJ4 (NCT02305849)                           | RA; inadequate response to MTX | Phase 3, randomized, double-blind, placebo-controlled, parallel-group | Placebo to 100 mg or 150 mg at Week 12 or 28<sup>c</sup>, 100 mg, 150 mg | 518                          | 52                        | Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, and 52 | Baseline and every 4 weeks until 52 weeks | Weeks 4, 8, 12, 20, 28, 40, and 52 | Week 4 or 8 | 11 |

Abbreviations: ACR, American College of Rheumatology; DAS28-CRP, 28-joint disease activity score based on C-reactive protein; DMARDs, disease-modifying antirheumatic drugs; IR, inadequate response; MTX, methotrexate; N/A, not available; PK, pharmacokinetic; RA, rheumatoid arthritis.

<sup>a</sup>Total number of patients who received at least one dose of the study drug.

<sup>b</sup>Patients receiving etanercept were excluded from the analysis.

<sup>c</sup>Inadequate responders in the placebo group were switched to either peficitinib 100 or 150 mg at week 12, and the remaining patients in placebo group were switched to peficitinib 100 or 150 mg at week 28.
A continuous time Markov model was applied to describe the probability of longitudinal ACR20 response rates. The rate constants for the transition between responding state (1) and non-responding state (0) are defined in Equations 1 and 2:

$$\lambda_{01} = \exp(\alpha_0 + \text{DE})$$

(1)

$$\lambda_{10} = \exp(\alpha_1 - \text{DE})$$

(2)

where $\lambda_{01}$ and $\lambda_{10}$ are the transition constants for transitions from state 0 to state 1 and from state 1 to state 0, and $\alpha_0/\alpha_1$ and DE are the intercepts and positive drug effect on the transition rates, respectively. The drug effect was assumed to have a sigmoidal maximum effective response ($E_{max}$) type intensity with time delay to reach the steady-state effect, as shown in Equation 3:

$$\text{DE} = E_{max} \times \frac{\text{AUC}_{24h}^n}{\text{EX}_{50} + \text{AUC}_{24h}^n} \times (1 - e^{-K_{eq} \times t})$$

(3)

where $\text{EX}_{50}$, $K_{eq}$, and n are drug exposure in AUC$_{24h}$ to provide the half-maximal effect, the equilibrium rate constant to reach the steady-state effect, and the Hill coefficient for the sigmoidal shape, respectively. Time (t) is defined as the number of weeks after the first administration of study drug.

Probabilities of the transitions between the states are shown in Equations 4 to 7:

$$p_{01} = \frac{\lambda_{01}}{\lambda_{01} + \lambda_{10}} (1 - \exp(- (\lambda_{01} + \lambda_{10}) \times \delta))$$

(4)

$$p_{00} = 1 - p_{01}$$

(5)

$$p_{10} = \frac{\lambda_{10}}{\lambda_{01} + \lambda_{10}} (1 - \exp(- (\lambda_{01} + \lambda_{10}) \times \delta))$$

(6)

$$p_{11} = 1 - p_{10}$$

(7)

where $p_{ab}$ and $\delta$ are the probabilities of transition from previous state ($a = 0$: non-responding state or $a = 1$: responding state) to the consecutive current state ($b = 0$: non-responding state or $b = 1$: responding state) and duration between the observations, respectively. ACR20-CRP at baseline was set to zero. Additive interindividual variability (IIV) was assumed in $\lambda_{01}$ to describe IV sensitivity to drug effect.

For assessment visits less than 4 weeks after the first administration of study drug (RAJ1 study only), a higher probability of transitioning to a responder from a non-responder ($p^{23}$) was assumed, which was equal to a probability of becoming a responder from a responder ($p^{31}$), in order to account for the patient’s high expectations of treatment during a clinical trial. A non-linear mixed effect model was constructed with NONMEM® version 7.3 software (ICON, Ellicott City, MD, USA) using the first-order conditional estimation method with the Laplacian likelihood option.
2.4 | DAS28-CRP model

Individual longitudinal DAS28-CRP measurements were modeled (Figure 1-B). Missing DAS28-CRP measurements were not imputed and patients who had only one DAS28-CRP measurement or no DAS28-CRP measurement at baseline were excluded from the analysis. Outliers were not defined throughout the modeling.

An indirect response model\(^{19}\) incorporating the inhibitory effect of the drug on the production rate constant of disease severity was applied to describe the time course of DAS28-CRP, as shown in Equation 8:

\[
\frac{d\text{DAS28-CRP}(t)}{dt} = \text{BASE} \times \text{DKEQ} \times \text{DE} - \text{DKEQ} \times \text{DAS28-CRP}(t) \tag{8}
\]

where BASE, DKEQ, and DE are the DAS28-CRP at baseline, production rate constant of disease severity, and drug effect, respectively. The drug effect on the production rate constant was assumed to have a sigmoidal \(E_{\text{max}}\) type intensity, as shown in Equation 9:

\[
\text{DE} = E_{\text{max}} \times \frac{\text{EX}_{50}}{\text{EX}_{50} + \text{AE}_{24h}} \tag{9}
\]

\(E_{\text{max}}\) was assumed to be 1, as it was estimated to be close to 1 in the preliminary analysis. Moreover, the placebo effect (PEFF) was added to the effect obtained from Equation 8 by exponentially increasing or decreasing change with time, as shown in Equation 10:

\[
\text{PEFF}(t) = \text{PA} \times (1 - e^{-\text{K}_{\text{IIV}} \times t}) \tag{10}
\]

where \(\text{PA}\) and \(\text{K}_{\text{IIV}}\) are the maximum placebo effect and rate constant to reach maximum placebo effect, respectively. \(\text{IIV}\) of \(\text{EX}_{50}\) for sensitivity to drug effect was assumed to have log-normal distribution. \(\text{IIV}\) of \(\text{PA}\) was defined as an additive to allow both upward and downward time courses during placebo treatment. Residual random effect was included as an additive variance. A non-linear mixed effect model was constructed with NONMEM software using the first-order conditional estimation method with interaction option (FOCEI).

2.5 | Covariate exploration

In both the ACR20 and DAS28-CRP models, the effect on \(\text{EX}_{50}\) of the following candidate covariates was investigated: demographics; laboratory test values at baseline; disease activity at baseline; prior treatment for RA; history of inadequate response to prior treatment; and use of concomitant medication. Details of the covariates investigated are listed in Table 2.

The candidate covariates were evaluated as target covariates with significant decrease in objective functional value (OFV) (6.64) by adding one candidate covariate at a time in the base model. For target covariates, the covariate exploration was undertaken using stepwise forward addition (significance level \(p < 0.01\)) followed by backward elimination (significance level \(p < 0.001\)). The relationship between covariates having continuous value and PK parameters was modeled using a power function centralized by a representative value as arithmetic mean of the covariates (Equation 11):

\[
\text{Category} | \text{Candidate covariates (units)}
\]

| Demographics | Age (years), BMI (kg/m\(^2\)), BSA (m\(^2\)), LBM (kg), weight (kg), gender |
| Laboratory test values at baseline | Serum albumin (g/L), ALT (U/L), AST (U/L), ALP (U/L), total bilirubin (μmol/L), CPK (U/L), total protein (g/L), tLDL cholesterol (mmol/L), creatinine (μmol/L), urate (μmol/L), teGFR (mL/min/1.73\(^2\)), hematocrit, hemoglobin (g/L), terythrocyte count (10\(^6\)/L), lymphocyte count (10\(^3\)/L), platelets count (10\(^9\)/L) |
| Disease severity at baseline | CRP (mg/L), ESR (mm/h), DAS28-CRP, DAS28-ESR, HAQ-DI score, SDAI, RA duration (years), stage of RA\(^a\) |
| Prior treatment | bDMARDs, TNF inhibitors |
| History of inadequate response to prior treatment | MTX, bDMARDs, csDMARDs |
| Concomitant medication | csDMARDs, MTX, steroids, prednisolone |

Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; b, biological; BMI, body mass index; BSA, body surface area; CPK, creatinine kinase; CRP, C-reactive protein; cs, conventional synthetic; DAS28, 28-joint disease activity score; DMARD, disease-modifying antirheumatic drug; eGFR, estimated glomerular filtration rate calculated with the modification of diet in renal disease (MDRD) method; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire – Disability Index; LBM, lean body mass; LDL, low-density lipoprotein; MTX, methotrexate; RA, rheumatoid arthritis; SDAI, simplified disease activity index; TNF, tumor necrosis factor.

\(^a\)Stage I/II vs. III/IV.
where \( P_i, \theta_1, \theta_2, \) and \( \text{cov} \) are the individual parameter, the population mean parameter with the mean value of the covariate \([\text{mean}+\text{sd} \times \text{cov}]\), the exponent of the power function, and the covariate, respectively. For categorical covariates, a fractional difference was modeled using a multiplicative function (Equation 12):

\[
P_i = \theta_1 \times \theta_2^{\text{cov}}
\]

where \( \theta_2 \) and \( \text{COV} \) are the coefficient and the class of covariate (yes: \( \text{COV}=1 \); no: \( \text{COV}=0 \)), respectively. In the final model, the effects of selected covariates on ACR20 response rate and change from baseline in DAS28-CRP were assessed.

In order to assess the influence of each target covariate on the drug effect, the odds ratio (OR) of ACR20 and the change in effect size of DAS28-CRP were calculated and compared to each other using the constructed models, with each mean value of the covariate (mean) or higher value by 1 standard deviation (SD) from the mean (mean+1SD) for continuous covariates, and \( \text{COV}=0 \) (reference) or \( \text{COV}=1 \) (with covariate) for categorical covariates. ORs for ACR20 were calculated from probability using Equation 13:

\[
\text{OR} = \frac{P_{01}(\text{mean}+1\text{SD or with covariate})}{P_{00}(\text{mean or reference})} \times \frac{P_{01}(\text{mean or reference})}{P_{00}(\text{mean or reference})}
\]

The change in effect size of DAS28-CRP was calculated using the simulated DAS28-CRP change from baseline with mean+1SD covariate divided by the simulated change from baseline with mean covariate at week 12, following treatment with peficitinib 150 mg (Equation 14).

\[
\text{Change in effect size} = \frac{\text{DAS28-CRP change from baseline(\text{mean}+1\text{SD or with covariate})}}{\text{DAS28-CRP change from baseline(\text{mean or reference})}}
\]

### Predictive performance

The predictive performance of the final ACR20 and DAS28-CRP models was evaluated by visual predictive check (VPC) using SAS version 9.4 or Perl-speaks-NONMEM version 4.4.8. VPC was constructed based on the parameter estimates of the final model and 1000 datasets generated from the original model.

### Results

#### Datasets and demographic summary

Summary statistics of the demographics and baseline disease characteristics of patients are presented in Table 3. The ACR20 dataset included 9912 ACR20-CRP response rate data points from 1057 patients and the DAS28-CRP dataset included 11732 DAS28-CRP data points from 1078 patients.

#### Exposure parameters

The mean (SD, minimum–maximum) individual post hoc AUC\(_{24\ h}\) following treatment with peficitinib 25 mg, 50 mg, 100 mg, and 150 mg was 251.9 (43.26, 190.2–415.6), 507.4 (100.0, 342.9–828.1), 1088 (264.6, 533.5–2002), and 1702 (410.7, 752.8–3418), respectively.

#### ACR20 model

The continuous time Markov model was constructed to describe the probability of ACR20 response. The following were defined as target covariates: body surface area (BSA), lean body mass (LBM), prior bDMARD treatment, prior tumor necrosis factor (TNF) inhibitor treatment, total bilirubin, creatinine kinase (CPK), DAS28-CRP, DAS28 based on erythrocyte sedimentation rate (DAS28-ESR), and simplified disease activity index (SDAI). The forward addition step and backward elimination steps revealed that DAS28-CRP and total bilirubin at baseline had a significant effect on \( \text{EX}_{50} \), expressed as follows (Equation 15):

\[
\text{EX}_{50i} = 693 \times \left( \frac{\text{DAS28-CRP}_i}{5.3} \right)^{-0.109} \times \left( \frac{\text{total bilirubin}_i}{10} \right)^{-0.445}
\]

where DAS28-CRP, and total bilirubin represent the DAS28-CRP and total bilirubin at baseline of the \( i \)th subject. The parameter estimates of the ACR20 model are shown in Table 4. The equation for predicted individual \( \text{EX}_{50} \) above, indicated that \( \text{EX}_{50} \) tended to decrease in patients with high DAS28-CRP and total bilirubin levels at baseline. The model predicted ACR20 response rates at 12 weeks for peficitinib 150 mg to be 65.6% and 68.4% with observed mean and mean+1SD DAS28-CRP measurements at baseline of 5.3 and 6.29 in the phase 2 and phase 3 studies, respectively. The model predicted ACR20 response rates to be 65.6% and 67.4% when the observed mean and mean+1SD total bilirubin levels at baseline were 10 \( \mu \text{mol/L} \) and 13.8 \( \mu \text{mol/L} \), respectively. The standard error for each parameter was calculated in NONMEM based on an S matrix to converge the covariance step. The VPC plots suggested an adequate predictive performance (Figure 2).

#### DAS28-CRP model

The indirect response model incorporating the effect of drug inhibition on the production rate constant of disease severity was constructed to describe the time course of DAS28-CRP. The target covariates CRP, ESR, DAS28-CRP, DAS28-ESR, SDAI, RA duration, concomitant csDMARD treatment, concomitant methotrexate (MTX) treatment, and inadequate response to prior MTX treatment were selected. The forward addition step and backward elimination steps revealed that CRP at baseline and concomitant MTX treatment had a significant effect on \( \text{EX}_{50} \) (Equation 16):

\[
\text{EX}_{50i} = 3630 \times \left( \frac{\text{CRP}_i}{25} \right)^{-0.218} \times (0.653)^{\text{MTXCD}_i}
\]
where CRP and MTXCD represent the CRP level and concomitant MTX treatment at baseline of the \( j \)th subject. The parameter estimates of the DAS28-CRP model are shown in Table 5. The equation for predicted individual \( \text{EX}_50 \) above, indicated that \( \text{EX}_50 \) tended to decrease for patients with high CRP at baseline and concomitant use of MTX. The model predicted that typical DAS28-CRP changes from baseline at 12 weeks for peficitinib 150 mg were –1.8 and –1.9 with an observed mean and mean+1SD CRP level at baseline of 25 mg/L and 47.7 mg/L in the phase 2 and phase 3 studies, respectively. The model-predicted DAS28-CRP changes from baseline were –1.8 and –2.2 without and with concomitant use of MTX, respectively. The standard error for each parameter was calculated in NONMEM based on an S matrix to converge the covariance step. The VPC plots suggested an adequate predictive performance (Figure 3).

### 3.5 Comparison of the effect of target covariates

The following 15 covariates were selected as target covariates in the ACR20 model or DAS28-CRP model: BSA; LBM; total bilirubin; CPK; CRP; ESR; DAS28-CRP; DAS28-ESR; SDAI; RA duration; prior bDMARD treatment; prior TNF inhibitor treatment; concomitant csDMARD treatment; concomitant MTX treatment;
| Parameter | Estimate | SE  | RSE  | Variability[^a] | Shrinkage |
|-----------|----------|-----|------|----------------|-----------|
| Intercept of $\lambda_{01}$ | -3.02   | 0.0829 | 2.7% | —              | —         |
| Intercept of $\lambda_{10}$ | -1.41   | 0.0944 | 6.7% | —              | —         |
| EX\(_{50}\) (ng.h/mL) | 693     | 62.2  | 9.0% | —              | —         |
| $E_{\max}$ | 2.56   | 0.219 | 8.6% | —              | —         |
| $K_{eq}$ | 0.120   | 0.0127 | 10.6% | —              | —         |
| Hill coefficient | 2.05   | 0.460 | 22.4% | —              | —         |
| Covariate, DAS28-CRP on $E_{\max}$ | -1.09  | 0.188 | 17.2% | —              | —         |
| Covariate, total bilirubin on $E_{\max}$ | -0.445 | 0.0950 | 21.3% | —              | —         |
| Random effect of IIV on $\lambda_{01}$ | 1.91   | 0.210 | 11.0% | 239.9%         | 26.1%     |

Abbreviations: ACR, American College of Rheumatology; CRP, C-reactive protein; DAS28, 28-joint disease activity score; $E_{\max}$, maximum effective response; EX\(_{50}\), half-maximal effective area under the concentration–time curve for 0–24 h after dosing; $K_{eq}$, equilibrium rate constant to reach the steady-state effect; OFV, objective function value; RSE, relative standard error; SE, standard error; $\lambda_{01}$, transition constant for transitions from state 0 to state 1; $\lambda_{10}$, transition constant for transitions from state 1 to state 0; $\omega^2$, diagonal elements of variance–covariance matrix of random effects on subject-level parameters.

[^a]Interindividual variability (IIV) was calculated as $\sqrt{(\exp(\omega^2)-1)\times100}$ (%), OFV=7158.399.

FIGURE 2 Visual predictive check of the ACR20 model. Black circles, observed response rate in each clinical study; black solid curve and pink area, the median and 2.5th/97.5th percentiles of the simulated data, respectively. ACR, American College of Rheumatology; RAJ1, phase 2 study; RAJ3 and RAJ4, phase 3 studies.
and an inadequate response to prior MTX treatment. The relationship between the ORs of ACR20 response and changes in effect size of DAS28-CRP by the selected covariates on EX50 was strongly correlated, as shown in Figure 4.

4 | DISCUSSION

This report is the first analysis to characterize the exposure–response relationships for ACR20 response rate and DAS28-CRP

| Parameter                          | Estimate | SE    | RSE  | Variability | Shrinkage |
|------------------------------------|----------|-------|------|-------------|-----------|
| PA                                 | -0.782   | 0.0430| 5.5% | —           | —         |
| Placebo rate constant              | 0.369    | 0.0117| 3.2% | —           | —         |
| EX_{50} (ng/mL)                    | 3630     | 363   | 10.0%| —           | —         |
| Production rate constant           | 0.0816   | 0.00110| 1.3%| —           | —         |
| Covariate, CRP on E_{max}          | -0.218   | 0.0433| 19.9%| —           | —         |
| Covariate, concomitant MTX on E_{max} | 0.653   | 0.0725| 11.1%| —           | —         |
| Random effect of IIV on PA         | 1.04     | 0.0570| 5.5% | 135.2%      | 11.2%     |
| Random effect of IIV on EX50       | 1.10     | 0.0889| 8.1% | 141.6%      | 31.0%     |
| Additive residual error            | 0.538    | 0.00170| 0.3%| —           | 6.0%      |

**Table 5** Parameter estimates of the DAS28-CRP model

EX_{50}, half-maximal effective area under the concentration–time curve for 0–24 h after dosing; E_{max}, maximum effective response; MTX, methotrexate; OFV, objective function value; PA, maximum placebo effect; RSE, relative standard error; SE, standard error; ω², diagonal elements of variance–covariance matrix of random effects on subject-level parameters.

Interindividual variability (IIV) was calculated as √(exp(ω²)-1)×100 (%), OFV=1832.829.

**Figure 3** Visual predictive check of the DAS28-CRP model. Black circles, observed response rate in each clinical study; black solid curve and pink area, the median and 2.5th/97.5th percentiles of the simulated data, respectively. CRP, C-reactive protein; DAS28, 28-joint disease activity score; RAJ1, phase 2 study; RAJ3 and RAJ4, phase 3 studies.

**Figure 4**
measurements in patients with RA after once-daily administration of peficitinib. A previous phase 2 study identified a dose response for the efficacy of peficitinib in patients with moderate-to-severe RA; similarly, phase 3 studies enrolling patients with RA and an inadequate response either to prior DMARDs or methotrexate treatment showed that efficacy outcomes tended to be numerically higher with peficitinib 150 mg versus 100 mg. This trend was observed consistently across the phase 2 and phase 3 studies with both the ACR20 response rate and change from baseline in DAS28-CRP. By developing an exposure–response model, the magnitude of covariate effects could be explored to inform the optimal use of peficitinib in patients with RA.

ACR20 response rate is treated as a binary categorical variable (response vs. non-response). In order to model binary categorical variables, a logistic regression model with generalized estimating equations can be used, as has been applied previously in the development of models for ACR20 response rates following tofacitinib and baricitinib treatment. A continuous time Markov model has the advantage of enabling serial correlation to be modeled within subjects when observations are taken at irregular time points; a continuous time multistate Markov model has previously been used to develop an exposure–response model based on data from certolizumab pegol clinical trials in RA patients and to describe the dynamics of diarrhea events in patients treated with a combination of lumetuzumab and pertuzumab. In the present study, a continuous time Markov model was applied to describe the probability of ACR20 response, which decreased the OFV significantly compared with a logistic regression model without considering any association between consecutive responses by Markov element. Moreover, the significant improvement in OFV by introducing a higher p01 (the probability of transition from non-response state to a response state) applied at measurements up to 4 weeks after first administration of study drug suggested that an individual’s ACR20 response just after the start of treatment could be raised by the patient’s subjective high expectations of treatment in a clinical trial. This view may be supported by the recommendation that new DMARD treatments should be continued at least for 3–6 months for exact evaluation of their efficacy. VPC showed that the model generally captured the observed time course for ACR20 response rate.

The indirect response model was applied to describe the time course profile of DAS28-CRP. VPC strongly suggested that the model predictions were consistent with the observed data. The placebo effect could be adequately estimated by including additive IIV to describe both upward and downward time courses found in the placebo treatment group.

The finding that covariates relating to severity of RA, namely DAS28-CRP or CRP levels at baseline, were identified as significant covariates in both the final ACR20 and DAS28-CRP models indicated that baseline severity of disease correlated with the magnitude of the antirheumatic treatment response; this observation was similar to the previous findings for an etanercept ACR20 response model and an abatacept DAS28-CRP model. During covariate exploration using the DAS28-CRP model, CRP level at baseline was selected rather than DAS28-CRP, with the lowest OFV in the first forward addition step, while DAS28-CRP at baseline was not selected in the second forward addition step due to moderate correlation with CRP level (r = 0.51). Moreover, concomitant use of MTX treatment was selected as a significant covariate on EXp0 in the final DAS28-CRP model, which indicated that concomitant use of MTX increased the response. Considering that the peficitinib package insert carries the precaution that the product should be used in patients who have previously been treated with at least one antirheumatic drug, including methotrexate, but apparently still have disease-attributed symptoms, the concomitant use of MTX with peficitinib is feasible. On the other hand, the mechanism behind the significant effect of baseline total bilirubin in the final ACR20 model was unknown, as it was not selected as a significant covariate in a previous population PK model of peficitinib. The simulation results using our final ACR20 and DAS28-CRP models suggested no requirement for dose adjustment based on DAS28-CRP, concomitant MTX treatment, CRP, or total bilirubin at baseline. Caution should be used when applying these models to predict covariate effects in non-Asian patients, as the models were constructed using PK data from an Asian population.

A guidance document for developing drug products for RA treatment from the United States Food and Drug Administration suggests that continuous efficacy variables, such as DAS28, may be more sensitive in terms of assessing the dose response in efficacy and are recommended over dichotomous endpoints, such as ACR20 response. Achieving precision of model estimates for ACR20 response rate was generally challenging compared to the continuous variable of DAS28-CRP. In this analysis, the two separately constructed models for each of ACR20 response and DAS28-CRP provided not only a good description of observed treatment response over time, but also consistent results regarding the effect of
covariates on EX50; measurements of baseline disease severity were selected as significant covariates in both models, and target covariates had similar magnitudes of effect on the OR in the ACR20 model and on changes in effect size in the DAS28-CRP model. The trend of covariate effects showed the similarity between two models, which is to be expected considering that both parameters are key efficacy variables for RA treatment. On the other hand, the difference between these two models was that only the ACR20 model could incorporate a patient’s subjective expectation of a positive result just after the start of the treatment.

In conclusion, exposure–response models of peficitinib efficacy in RA patients for time courses of ACR20 response rates and DAS28-CRP measurements were constructed using a continuous time Markov model and an indirect response model. The covariates selected for the model suggested that the baseline severity of disease correlated with the magnitude of the antirheumatic treatment response. Considering the similarities and differences between the two, both the ACR20 response rate model and DAS28-CRP model may have relevant applications for the development of RA treatment.

ACKNOWLEDGMENTS

Astellas Pharma Inc. sponsored all studies and analyses. The authors thank all the medical institutions and physicians who participated in the included studies for their cooperation. The authors thank TIS Inc. for programing support and Iona Easthope of Cello Health MedErgy (Europe) for providing medical writing assistance and editorial support, which were funded by Astellas Pharma Inc.

CONFLICT OF INTEREST

J Toyoshima, M Shibata, Y Kaneko, H Izutsu, and T Nishimura are full-time employees of Astellas Pharma Inc., Tokyo, Japan.

A Kaibara was a full-time employee of Astellas Pharma Inc., Tokyo, Japan, at the time of analysis. He is currently a full-time employee of Eli Lilly Japan K.K., Tokyo, Japan.

AUTHOR CONTRIBUTIONS

J.T. wrote the article. All authors were involved with revising this article. J.T., M.S., T.N., and A.K. planned the analysis, and J.T. conducted the analysis. Y.K. was the lead statistician responsible for data handling for each study. H.I. was the study leader for peficitinib and contributed to the planning and conduct of the clinical studies.

DATA AVAILABILITY STATEMENT

Researchers may request access to anonymized participant-level data, trial-level data and protocols from Astellas sponsored clinical trials at www.clinicalstudydatarequest.com. For the Astellas criteria on data sharing see: https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Astellas.aspx

REFERENCES

1. O’Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med. 2004;350(25):2591-2602. https://doi.org/10.1056/NEJMoa040226

2. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205-2219. https://doi.org/10.1056/NEJMra1004965

3. Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960-977. https://doi.org/10.1136/annrheumdis-2016-210715

4. Lau CS, Chia F, Dans L, et al. 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. Int J Rheum Dis. 2019;22(3):357-375. https://doi.org/10.1111/1756-185X.13513

5. Zampeli E, Vlachoyiannopoulos PG, Tziofas AG. Treatment of rheumatoid arthritis: unraveling the conundrum. J Autoimmun. 2015;65:1-18. https://doi.org/10.1016/j.jaut.2015.10.003

6. Ito M, Yamazaki S, Yamagami K, et al. A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model. J Pharmacol Sci. 2017;133(1):25-33. https://doi.org/10.1016/j.jpfs.2016.12.001

7. Baneree S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK–STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017;77(5):521-546. https://doi.org/10.1007/s40265-017-0701-9

8. O’Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013;72(suppl 2):ii111-ii115. https://doi.org/10.1136/annrheumdis-2012-202576

9. Takeuchi T, Tanaka Y, Iwasaki M, Ishikura H, Saeki S, Kaneko Y. Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study. Ann Rheum Dis. 2016;75(6):1057-1064. https://doi.org/10.1136/annrheumdis-2015-208279

10. Tanaka Y, Takeuchi T, Tanaka S, et al. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3). Ann Rheum Dis. 2019;78(10):1320-1332. https://doi.org/10.1136/annrheumdis-2019-215163

11. Takeuchi T, Tanaka Y, Tanaka S, et al. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. Ann Rheum Dis. 2019;78(10):1305-1319. https://doi.org/10.1136/annrheumdis-2019-215164

12. Markham A, Keam SJ. Peficitinib: first global approval. Drugs. 2019;79(8):887-891. https://doi.org/10.1007/s40265-019-01131-y

13. Astellas Pharma Korea, Inc. Drug details: 50 mg Smyraf (peficitinib hydrobromide). https://nedrug.mfds.go.kr/ppb/CCBBB01/getTemporalDetailItemSeq=202000404. Accessed March 4, 2020.

14. Astellas Pharma Taiwan, Inc. Drug details: 50 mg Smyraf (peficitinib hydrobromide). https://info.fda.gov.tw/MLMS/H0001D.aspx?Type=Lic&LicId=52027856. Accessed June 4, 2020.

15. Astellas Pharma Korea, Inc. Drug details: 100 mg Smyraf (peficitinib hydrobromide). https://nedrug.mfds.go.kr/ppb/CCBBB01/getTemporalDetailItemSeq=202000403. Accessed March 4, 2020.

16. Astellas Pharma Taiwan, Inc. Drug details: 100 mg Smyraf (peficitinib hydrobromide). https://info.fda.gov.tw/MLMS/H0001D.aspx?Type=Lic&LicId=52027857. Accessed June 4, 2020.

17. Toyoshima J, Shibata M, Kaibara A, Kaneko Y, Izutsu H, Nishimura T. Population pharmacokinetic analysis of peficitinib in patients with rheumatoid arthritis. Br J Clin Pharmacol. 2020. (In Press). https://doi.org/10.1111/bcp.14605

18. Jones RH, Xu S, Grunwald GK. Continuous time markov models for binary longitudinal data. Biometrical J. 2006;48(3):411-419. https://doi.org/10.1002/bimj.200510224
19. Daynka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. *J Pharmacokinet Biopharm*. 1993;21(4):457-478. https://doi.org/10.1007/BF01061691

20. Lindbom L, Pihlgren P, Jonsson N. PsN-ToolKit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. *Comput Methods Programs Biomed*. 2005;79(3):241-257. https://doi.org/10.1016/j.cmpb.2005.04.005

21. Bonate PL. *Pharmacokinetic-Pharmacodynamic Modeling and Simulation*, (2nd edn.) US: Springer; 2011. https://doi.org/10.1007/978-1-4419-9485-1

22. Lamba M, Hutmacher MM, Furst DE, et al. Model-informed development and registration of a once-daily regimen of extended-release tofacitinib. *Clin Pharmacol Ther*. 2017;101(6):745-753. https://doi.org/10.1002/cpt.576

23. Zhang X, Chua L, Ernest C, Macias W, Rooney T, Tham LS. Dose/exposure-response modeling to support dosing recommendation for phase III development of baricitinib in patients with rheumatoid arthritis. *CPT Pharmacometrics Syst Pharmacol*. 2017;6(12):804-813. https://doi.org/10.1002/psp4.12251

24. Lacroix BD, Karlsson MO, Friberg LE. Simultaneous exposure-response modeling of ACR20, ACR50, and ACR70 improvement scores in rheumatoid arthritis patients treated with certolizumab pegol. *CPT Pharmacometrics Syst Pharmacol*. 2014;3(10):1-11. https://doi.org/10.1038/psp.2014.41

25. Xu C, Ravva P, Dang JS, et al. A continuous-time multistate Markov model to describe the occurrence and severity of diarrhea events in metastatic breast cancer patients treated with lumretuzumab in combination with pertuzumab and paclitaxel. *Cancer Chemother Pharmacol*. 2018;82(3):395-406. https://doi.org/10.1007/s00280-018-3621-9

26. Davis JM, Matteson EL. My treatment approach to rheumatoid arthritis. *Mayo Clinic Proceedings*. Vol 87. Elsevier Ltd. 2012;87(7):659-673. https://doi.org/10.1016/j.mayocp.2012.03.011

27. Lee H, Kimko HC, Rogge M, Wang D, Nestorov I, Peck CC. Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. *Clin Pharmacol Ther*. 2003;73(4):348-365. https://doi.org/10.1016/s0003-9236(02)17635-1

28. Li X, Roy A, Murthy B. Population pharmacokinetics and exposure-response relationship of intravenous and subcutaneous abatacept in patients with rheumatoid arthritis. *J Clin Pharmacol*. 2019;59(2):245-257. https://doi.org/10.1002/jcph.1308

29. US Food and Drug Administration. Guidance document. Rheumatoid arthritis: developing drug products for treatment. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rheumatoid-arthritis-developing-drug-products-treatment. 2013.

30. Hu C. Exposure-response modeling of clinical end points using latent variable indirect response models. *CPT Pharmacometrics Syst Pharmacol*. 2014;3(6):e117. https://doi.org/10.1038/psp.2014.15

---

**How to cite this article:** Toyoshima J, Kaibara A, Shibata M, Kaneko Y, Izutsu H, Nishimura T. Exposure–response modeling of peficitinib efficacy in patients with rheumatoid arthritis. *Pharmacol Res Perspect*. 2021;9:e00744. https://doi.org/10.1002/prp2.744